Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: A meta-analysis

American Journal of Nephrology

Volumn 39, Issue 2, 2014, Pages 130-141

  Susantitaphong, Paweena ^a,b,d   Alqahtani, Fahad ^c   Jaber, Bertrand L ^a,b  

^a ST ELIZABETH'S MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

^d CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Functional iron deficiency anemia; Hemodialysis; Inflammation; Intravenous iron therapy; meta analysis; Oxidative stress

Indexed keywords

ERYTHROPOIETIN; FERRIC HYDROXIDE; FERRITIN; FERROUS CHLORIDE; FERROUS GLUCONATE; FERUMOXYTOL; HEMOGLOBIN; IRON; IRON DEXTRAN; IRON OXIDE; IRON POLYMALTOSE; IRON SACCHARATE; MALONALDEHYDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRANSFERRIN; 3,4 METHYLENEDIOXYAMPHETAMINE; ALPHA TOCOPHEROL; ASCORBIC ACID; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN;

DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ERYTHROCYTE; FERRITIN BLOOD LEVEL; HEART DISEASE; HEMODIALYSIS PATIENT; HUMAN; INFECTION; INFLAMMATION; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; IRON THERAPY; META ANALYSIS; NEUTROPHIL; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY BURST; RETICULOCYTE HEMOGLOBIN CONTENT; REVIEW; ARTICLE; CARDIOVASCULAR SYMPTOM; COCHRANE LIBRARY; FUNCTIONAL IRON DEFICIENCY ANEMIA; HEMOGLOBIN BLOOD LEVEL; NEUTROPHIL COUNT; SYSTEMATIC REVIEW; TRANSFERRIN BLOOD LEVEL; VITAMIN BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ANEMIA, IRON-DEFICIENCY; BIOLOGICAL MARKERS; FEMALE; HEMATINICS; HUMANS; INJECTIONS, INTRAVENOUS; IRON COMPOUNDS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; YOUNG ADULT;

EID: 84893662996     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000358336     Document Type: Review

References (69)

1. KDOQI; National Kidney Foundation: KDO-QI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006; 47(suppl 3):S11-S145.
2. Locatelli F, Covic A, Eckardt KU, et al: Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 2009; 24:348-354.
3. Locatelli F, Aljama P, Bárány P, et al: Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19(suppl 2):ii1-ii47.
4. Gillespie RS, Wolf FM: Intravenous iron therapy in pediatric hemodialysis patients: a meta-analysis. Pediatr Nephrol 2004; 19:662-666.
5. Rozen-Zvi B, Gafter-Gvili A, Paul M, et al: Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 2008; 52:897-906.
6. Albaramki J, Hodson EM, Craig JC, et al: Par-enteral versus oral iron therapy for adults and children with chronic kidney disease. Co-chrane Database Syst Rev 2012; 1:CD007857.
7. Coyne DW, Kapoian T, Suki W, et al: Ferric gluconate is highly efficacious in anemic he-modialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007; 18:975-984.
8. Kapoian T, O'Mara NB, Singh AK, et al: Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 2008; 19:372-379
9. FDA Drug Safety Communication: modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents (ESAs) in chronic kidney disease. 2011. http://www.fda.gov/Drugs/DrugSafety/ucm259639. htm.
10. Drüeke TB, Locatelli F, Clyne N, et al: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355:2071-2084.
11. Singh AK, Szczech L, Tang KL, et al: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:2085-2098.
12. Pfeffer MA, Burdmann EA, Chen CY, et al: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361:2019-2032.
13. Koulouridis I, Alfayez M, Trikalinos TA, et al: Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis 2013; 61:44-56.
14. Brunelli SM, Monda KL, Burkart JM, et al: Early trends from the Study to Evaluate the Prospective Payment System Impact on Small Dialysis Organizations (STEPPS). Am J Kidney Dis 2013; 61:947-956.
15. Hirth RA, Turenne MN, Wheeler JR, et al: The initial impact of Medicare's new prospective payment system for kidney dialysis. Am J Kidney Dis 2013; 62:662-669.
16. Vaziri ND: Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis 2013; 61:992-1000.
17. KDIGO Anemia Work Group: KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int 2012; 2(suppl): 279-335.
18. Kalantar-Zadeh K, Höffken B, Wünsch H, et al: Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 1995; 26: 292-299.
19. Horowitz J, Agarwal A, Huang F, et al: Empirical methods to calculate an erythropoie-sis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease. J Manag Care Pharm 2009; 15:741-750.
20. Sharma A, Yee J, Gandra SR, et al: Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population. Curr Med Res Opin 2010; 26:2679-2687.
21. Wells GA, Shea B, O'Connell D, et al: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in me-ta-analyses. http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp.
22. Jadad AR, Moore RA, Carroll D, et al: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17:1-12.
23. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188.
24. 2 index? Psychol Methods 2006; 11:193-206.
25. Egger M, Davey Smith G, Schneider M, et al: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-634.
26. Allegra V, Mengozzi G, Vasile A: Iron deficiency in maintenance hemodialysis patients: assessment of diagnosis criteria and of three different iron treatments. Nephron 1991; 57: 175-182.
27. Sunder-Plassmann G, Hörl WH: Safety of intravenous injection of iron saccharate in hae-modialysis patients. Nephrol Dial Transplant 1996; 11:1797-1802.
28. Mittman N, Sreedhara R, Mushnick R, et al: Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am J Kidney Dis 1997; 30:912-922.
29. Saltissi D, Sauvage D, Westhuyzen J: Comparative response to single or divided doses of parenteral iron for functional iron deficiency in hemodialysis patients receiving erythro-poietin (EPO). Clin Nephrol 1998; 49:45-48.
30. Macdougall IC, Chandler G, Elston O, et al: Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit. Am J Kidney Dis 1999; 34(suppl 2):S40-S46.
31. Agarwal R, Davis JL, Hamburger RJ: A trial of two iron-dextran infusion regimens in chronic hemodialysis patients. Clin Nephrol 2000; 54:105-111.
32. Besarab A, Amin N, Ahsan M, et al: Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000; 11:530-538.
33. Fishbane S, Shapiro W, Dutka P, et al: A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 2001; 60:2406-2411.
34. Huang JY, Wu MS, Wu CH: The effect of an iron supplement on serum aluminum level and desferrioxamine mobilization test in he-modialysis patients. Ren Fail 2001; 23: 789-795.
35. Kosch M, Bahner U, Bettger H, et al: A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant 2001; 16:1239-1244.
36. Bolaños L, Castro P, Falcón TG, et al: Continuous intravenous sodium ferric gluconate improves efficacy in the maintenance phase of EPOrHu administration in hemodialysis patients. Am J Nephrol 2002; 22:67-72.
37. Chang CH, Chang CC, Chiang SS: Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients. Clin Nephrol 2002; 57:136-141.
38. Kooistra MP, Kersting S, Gosriwatana I, et al: Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion. Eur J Clin Invest 2002; 32(suppl 1):36-41.
39. Mulay A, Nadler S, Burns K, Zimmerman D, Knoll G: Intravenous iron reduces erythro-poietin use and improves iron indices in he-modialysis patients with functional iron deficiency. J Am Soc Nephrol 2003; 14:706A.
40. Cavdar C, Temiz A, Yeniçerioglu Y, et al: The effects of intravenous iron treatment on oxi-dant stress and erythrocyte deformability in hemodialysis patients. Scand J Urol Nephrol 2003; 37:77-82.
41. Chuang CL, Liu RS, Wei YH, et al: Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients. Nephrol Dial Transplant 2003; 18:370-377.
42. Kaneko Y, Miyazaki S, Hirasawa Y, et al: Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients. Kidney Int 2003; 63:1086-1093.
43. Michelis R, Gery R, Sela S, et al: Carbonyl stress induced by intravenous iron during haemodialysis. Nephrol Dial Transplant 2003; 18:924-930.
44. Riedel MK, Morgenstern T: Iron replacement in hemodialysis patients with a normal serum ferritin level (in German). Dtsch Med Wochenschr 2004; 129:1849-1853.
45. Hodkova M, Dusilova-Sulkova S, Skalicka A, et al: Influence of parenteral iron therapy and oral vitamin E supplementation on neutro-phil respiratory burst in chronic hemodialysis patients. Ren Fail 2005; 27:135-141.
46. 2-microglobulin properties and levels. Nephrol Dial Transplant 2005; 20:1963-1969.
47. Eiselt J, Racek J, Opatrny K Jr, et al: The effect of intravenous iron on oxidative stress in he-modialysis patients at various levels of vitamin C. Blood Purif 2006; 24:531-537.
48. Schiesser D, Binet I, Tsinalis D, et al: Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases ep-oetin requirement in iron-replete haemodi-alysis patients. Nephrol Dial Transplant 2006; 21:2841-2845.
49. Warady BA, Zobrist RH, Finan E: Sodium ferric gluconate complex maintenance therapy in children on hemodialysis. Pediatr Nephrol 2006; 21:553-560.
50. Bovy C, Gothot A, Delanaye P, et al: Mature erythrocyte parameters as new markers of functional iron deficiency in haemodialysis: sensitivity and specificity. Nephrol Dial Transplant 2007; 22:1156-1162.
51. Coyne DW, Sims A, Bingel B: Results of an anemia management program to reduce high epoetin doses by targeted use of iv ferric glu-conate. Nephrol Nurs J 2008; 35:583-587.
52. Kapoian T: Challenge of effectively using erythropoiesis-stimulating agents and intravenous iron. Am J Kidney Dis 2008; 52(suppl):S21-S28.
53. Provenzano R, Schiller B, Rao M, et al: Feru-moxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4:386-393.
54. Bhat P, Gabaldon JA, Bhat JG: Efficacy of an anemia management strategy targeting higher transferrin saturation (TSAT) and ferritin levels using ferumoxytol. J Am Soc Nephrol 2010; 21:63A.
55. Chinnappa S, Bhandari S: Influence of intravenous iron therapy on novel markers of iron deficiency. Int J Artif Organs 2010; 33:297-301.
56. Rath T, Florschütz K, Kalb K, et al: Low-molecular-weight iron dextran in the management of renal anaemia in patients on haemo-dialysis: the IDIRA Study. Nephron Clin Pract 2010; 114:c81-c88.
57. Malovrh M, Hojs N, Premru V: The influence of need-based, continuous, low-dose iron replacement on hemoglobin levels in hemodial-ysis patients treated with erythropoiesis-stim-ulating agents. Artif Organs 2011; 35:63-68.
58. Stefánsson BV, Haraldsson B, Nilsson U: Acute oxidative stress following intravenous iron injection in patients on chronic hemodi-alysis: a comparison of iron-sucrose and iron-dextran. Nephron Clin Pract 2011; 118:c249-c256.
59. Weinberg E: Iron and infection. Microbiol Rev 1978; 42:45-66.
60. Boelaert JR, Daneels RF, Schurgers ML, et al: Iron overload in haemodialysis patients increases the risk of bacteraemia: a prospective study. Nephrol Dial Transplant 1990; 5:130-134.
61. Patruta SI, Edlinger R, Sunder-Plassmann G, et al: Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 1998; 9:655-663.
62. Guo D, Jaber BL, Perianayagam MC, King AJ, Pereira BJ, Balakrishnan VS: Impact of iron dextran on polymorphonuclear cell function among hemodialysis patients. Clin Nephrol 2002; 58:134-142.
63. Teehan GS, Bahdouch D, Ruthazer R, Bala-krishnan VS, Snydman DR, Jaber BL: Iron storage indices: novel predictors of bactere-mia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis 2004; 38: 1090-1094.
64. Teehan GS, Ruthazer R, Balakrishnan VS, Snydman D, Jaber BL: Iron storage indices and risk of bacterial infections in hemodialy-sis patients. Hemodial Int 2004; 8:226-232.
65. Brookhart MA, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Kshirsagar AV: Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol 2013; 24:1151-1158.
66. Buttarello M, Pajola R, Novello E, Rebeschini M, Cantaro S, Oliosi F, Naso A, Plebani M: Diagnosis of iron deficiency in patients undergoing hemodialysis. Am J Clin Pathol 2010; 133:949-954.
67. Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, Ganz T, Rivera S, Nis-senson AR, Salusky IB: Hepcidin: a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4:1051-1056.
68. Soininen K, Punnonen K, Matinlauri I, Kar-hapää P, Rehu M: Transferrin receptor expression on reticulocytes as a marker of iron status in dialyzed patients. Clin Chem Lab Med 2010; 48:1239-1245.
69. Wish JB: Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006; 1(suppl 1):S4-S8.